147 related articles for article (PubMed ID: 26990212)
1. Adjunct Histamine Blockers as Premedications to Prevent Carboplatin Hypersensitivity Reactions.
Mach CM; Lapp EA; Weddle KJ; Hunter RJ; Burns KA; Parker C; Brown J; Smith JA
Pharmacotherapy; 2016 May; 36(5):482-7. PubMed ID: 26990212
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients.
Navo M; Kunthur A; Badell ML; Coffer LW; Markman M; Brown J; Smith JA
Gynecol Oncol; 2006 Nov; 103(2):608-13. PubMed ID: 16797060
[TBL] [Abstract][Full Text] [Related]
3. Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer.
Jerzak KJ; Deghan Manshadi S; Ng P; Maganti M; McCuaig JM; Bulter M; Oza A; Mackay HJ
J Oncol Pharm Pract; 2018 Mar; 24(2):83-90. PubMed ID: 27856924
[TBL] [Abstract][Full Text] [Related]
4. Effect of Prophylactic Extended-Infusion Carboplatin on Incidence of Hypersensitivity Reactions in Patients with Ovarian, Fallopian Tube, or Peritoneal Carcinomas.
Pasternak AL; Link NA; Richardson CM; Rose PG
Pharmacotherapy; 2016 Jul; 36(7):723-30. PubMed ID: 27196693
[TBL] [Abstract][Full Text] [Related]
5. Premedication strategy for weekly paclitaxel.
Quock J; Dea G; Tanaka M; Gandara D; Lara P; Lau D
Cancer Invest; 2002; 20(5-6):666-72. PubMed ID: 12197222
[TBL] [Abstract][Full Text] [Related]
6. The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment.
O'Cearbhaill R; Zhou Q; Iasonos A; Hensley ML; Tew WP; Aghajanian C; Spriggs DR; Lichtman SM; Sabbatini PJ
Gynecol Oncol; 2010 Mar; 116(3):326-31. PubMed ID: 19944454
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin hypersensitivity reactions: a single institution experience.
Zorzou MP; Efstathiou E; Galani E; Bozas G; Kastritis E; Papadimitriou C; Dimopoulos MA; Bamias A
J Chemother; 2005 Feb; 17(1):104-10. PubMed ID: 15828452
[TBL] [Abstract][Full Text] [Related]
8. Histamine-2 (H
Foreman E; Polwart C; Walker A; Chambers P
Br J Clin Pharmacol; 2022 Sep; 88(9):4191-4198. PubMed ID: 35470452
[TBL] [Abstract][Full Text] [Related]
9. Successful re-treatment with taxol after major hypersensitivity reactions.
Peereboom DM; Donehower RC; Eisenhauer EA; McGuire WP; Onetto N; Hubbard JL; Piccart M; Gianni L; Rowinsky EK
J Clin Oncol; 1993 May; 11(5):885-90. PubMed ID: 8098057
[TBL] [Abstract][Full Text] [Related]
10. H1 + H2-receptor antagonists for premedication in anaesthesia and surgery: a critical view based on randomized clinical trials with Haemaccel and various antiallergic drugs.
Lorenz W; Doenicke A; Schöning B; Mamorski J; Weber D; Hinterlang E; Schwarz B; Neugebauer E
Agents Actions; 1980 Apr; 10(1 Pt 2):114-24. PubMed ID: 6155762
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of premedication, glucocorticosteroids, and H
Ikegawa K; Suzuki S; Nomura H; Enokida T; Yamazaki T; Okano S; Endo K; Saito S; Yamaguchi M; Tahara M
J Int Med Res; 2017 Aug; 45(4):1378-1385. PubMed ID: 28606015
[TBL] [Abstract][Full Text] [Related]
12. Impact of institutional interventions on the rate of paclitaxel hypersensitivity reactions.
Jao ME; Indorf AL; Segal EM; Miske A; Eaton KD; Marsolini T; Ghuman S
J Oncol Pharm Pract; 2024 Jan; 30(1):105-111. PubMed ID: 37021579
[TBL] [Abstract][Full Text] [Related]
13. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
Ann Oncol; 1997 Jun; 8(6):611-4. PubMed ID: 9261533
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer.
Gadducci A; Tana R; Teti G; Zanca G; Fanucchi A; Genazzani AR
Int J Gynecol Cancer; 2008; 18(4):615-20. PubMed ID: 18754135
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of premedication for non-ionic radio-contrast media hypersensitivity reactions in Korea.
Kim SH; Lee SH; Lee SM; Kang HR; Park HW; Kim SS; Cho SH; Min KU; Kim YY; Chang YS
Eur J Radiol; 2011 Nov; 80(2):363-7. PubMed ID: 20619990
[TBL] [Abstract][Full Text] [Related]
16. Hypersensitivity reaction to paclitaxel: nursing interventions.
Myers JS
Clin J Oncol Nurs; 2000; 4(4):161-3. PubMed ID: 11261096
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin Rechallenge After Hypersensitivity Reactions in Pediatric Patients With Low-Grade Glioma.
Shah AC; Minturn JE; Li Y; Belasco JB; Phillips PC; Kang TI; Cole KA; Waanders AJ; Pollack R; Didomenico C; Wildes C; Fisher MJ
Pediatr Blood Cancer; 2016 Jan; 63(1):21-6. PubMed ID: 26235452
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel premedication regimens.
Boehm DK; Maksymiuk AW
J Natl Cancer Inst; 1996 Apr; 88(7):463-5. PubMed ID: 8618242
[No Abstract] [Full Text] [Related]
19. Hypersensitivity Reactions: Priming Practice Change to Reduce Incidence in First-Dose Rituximab Treatment.
Laudati C; Clark C; Knezevic A; Zhang Z; Barton-Burke M
Clin J Oncol Nurs; 2018 Aug; 22(4):407-414. PubMed ID: 30035788
[TBL] [Abstract][Full Text] [Related]
20. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
Ottaiano A; Tambaro R; Greggi S; Prato R; Di Maio M; Esposito G; Scala F; Barletta E; Losito S; De Vivo R; Iaffaioli VR; Pignata S
Anticancer Res; 2003; 23(4):3465-8. PubMed ID: 12926091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
